154590-34-8

Basic information

• Product Name: tert-Butyl 4-(2-fluoro-4-nitrophenyl)piperazine-1-carboxylate
• Synonyms: 4-(2-Fluoro-4-nitrophenyl)piperazine, N1-BOC protected;tert-Butyl 4-(2-fluoro-4-nitrophenyl)piperazine-1-carboxylate;1-Boc-4-(2-Fluoro-4-nitrophenyl)piperazine, 97%;3-Fluoro-4-[4-(tert-butoxycarbonyl)piperazin-1-yl]nitrobenzene
• CAS NO: 154590-34-8
• Molecular Formula: C₁₅H₂₀FN₃O₄
• Molecular Weight: 325.3354032
• Mol File: 154590-34-8.mol
• Article Data: 29

Chemical Properties

• Melting Point: 153-155 °C(Solv: ethyl ether (60-29-7))
• Boiling Point: 453.5±45.0 °C(Predicted)
• Appearance: /Solid
• Density: 1.270±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 0.11±0.10(Predicted)
• CAS DataBase Reference: tert-Butyl 4-(2-fluoro-4-nitrophenyl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-(2-fluoro-4-nitrophenyl)piperazine-1-carboxylate(154590-34-8)
• EPA Substance Registry System: tert-Butyl 4-(2-fluoro-4-nitrophenyl)piperazine-1-carboxylate(154590-34-8)

Safety Data

• Hazardous Substances Data: 154590-34-8(Hazardous Substances Data)

Usage

General Description

Tert-Butyl 4-(2-fluoro-4-nitrophenyl)piperazine-1-carboxylate is a chemical compound that is commonly used in pharmaceutical research and drug development. It is classified as a piperazine derivative and contains a tert-butyl group, a fluoro substituent, and a nitro group. The compound's structure and functional groups make it a potential candidate for investigating the biological activities and pharmacological properties of piperazine-based molecules. Additionally, the compound's tert-butyl ester group may also contribute to its stability and bioavailability in medicinal formulations. Further research and studies are required to fully explore the potential applications of tert-Butyl 4-(2-fluoro-4-nitrophenyl)piperazine-1-carboxylate in the field of pharmaceutical science.

Upstream product

• 154590-40-6 3-[3-Fluoro-4-(4-tert-butoxycarbonylpiperazin-1-yl)phenyl]-5-methanesulfonyloxymethyl-2-oxazolidinone 
• 24424-99-5 di-tert-butyl dicarbonate 
• 154590-33-7 1-(2-fluoro-4-nitrophenyl)piperazine 
• 369-34-6 3,4-difluoronitrobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 154590-33-7 1-(2-fluoro-4-nitrophenyl)piperazine 

Relevant articles and documents

Indazole formamide compound as well as preparation method and application thereof

The invention belongs to the field of chemical medicines, and particularly relates to an indazole formamide compound as well as a preparation method and application thereof. The invention provides anindazole carboxamide compound or a pharmaceutically acce

Discovery of benzo[d]oxazole derivatives as the potent type-I FLT3-ITD inhibitors

Fms-like tyrosine kinase 3 (FLT3) has been considered as a potential drug target for the treatment of acute myeloid leukemia (AML), because of its high and aberrant expression in AML patients, especially the patients with FLT3-ITD mutation. Initiating from a hit compound (IC50: 500 nM against FLT3-ITD), a series of compounds were designed and synthesized based on benzo[d]oxazole-2-amine scaffold to discover new potent FLT3-ITD inhibitors. During the medicinal chemistry works, flexible molecular docking was used to provide design rationale and study the binding modes of the target compounds. Through the mixed SAR exploration based on the enzymatic and cellular activities, compound T24 was identified with potent FLT3-ITD inhibitory (IC50: 0.41 nM) and anti-proliferative (IC50: 0.037 μM against MV4-11 cells) activities. And the binding mode of T24 with “DFG-in” FLT3 was simulated by a 20-ns molecular dynamics run, providing some insights into further medicinal chemistry efforts toward novel FLT3 inhibitors in AML therapy.

RETRACTED ARTICLE: Design, synthesis of novel oxazolidino-amides/sulfonamides conjugates and their impact on antibacterial activity

Abstract: In view of generating new compounds for future drug development, we have synthesized oxazolidinones library of aryl amides and aryl sulfonamide derivatives. These compounds were screened in vitro against panel of susceptible and resistant Gram-p